Marks Group Wealth Management Inc Sells 482 Shares of Johnson & Johnson $JNJ

Marks Group Wealth Management Inc decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.9% during the second quarter, HoldingsChannel reports. The firm owned 3,930 shares of the company’s stock after selling 482 shares during the period. Marks Group Wealth Management Inc’s holdings in Johnson & Johnson were worth $600,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Woodmont Investment Counsel LLC increased its position in Johnson & Johnson by 4.4% during the 2nd quarter. Woodmont Investment Counsel LLC now owns 97,737 shares of the company’s stock valued at $14,929,000 after purchasing an additional 4,108 shares during the period. Grimes & Company Inc. increased its position in Johnson & Johnson by 3.4% during the 2nd quarter. Grimes & Company Inc. now owns 106,981 shares of the company’s stock valued at $16,341,000 after purchasing an additional 3,544 shares during the period. Three Bridge Wealth Advisors LLC increased its position in Johnson & Johnson by 15.2% during the 2nd quarter. Three Bridge Wealth Advisors LLC now owns 9,132 shares of the company’s stock valued at $1,395,000 after purchasing an additional 1,206 shares during the period. Hubbell Strickland Wealth Management LLC increased its position in Johnson & Johnson by 8.4% during the 2nd quarter. Hubbell Strickland Wealth Management LLC now owns 5,842 shares of the company’s stock valued at $892,000 after purchasing an additional 451 shares during the period. Finally, JSF Financial LLC increased its position in Johnson & Johnson by 2.2% during the 2nd quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock valued at $457,000 after purchasing an additional 65 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on JNJ shares. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a research report on Friday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Finally, Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $189.88.

Johnson & Johnson Stock Up 0.4%

JNJ stock opened at $188.95 on Wednesday. The firm has a 50 day moving average of $177.04 and a 200 day moving average of $163.18. The stock has a market capitalization of $455.06 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $189.92.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the business earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.